Molecule News and Research

RSS

Bionomics, Ironwood partner to develop and commercialize novel anti-anxiety compound

Ironwood Pharmaceuticals, Inc. and Bionomics Limited today announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics' investigational anti-anxiety compound BNC210 and other related compounds.

5 Jan 2012

First study to elucidate how statins reduce activation of abnormal blood clotting

People with high cholesterol are at risk of heart attack and stroke because atherosclerotic plaques within their arteries can rupture triggering the formation of a blood clot called an occlusive thrombus that cuts off the blood supply to their heart or brain.

5 Jan 2012

$Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer$

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.

4 Jan 2012

Study reveals possibility to selectively target and block crucial microRNA in liver cancer

A new study shows that it is possible to selectively target and block a particular microRNA that is important in liver cancer. The findings might offer a new therapy for this malignancy, which kills an estimated 549,000 people worldwide annually.

4 Jan 2012

MRC-funded study to explore pancreatic cancer

A promising line of attack against pancreatitis and pancreatic cancer is to be explored further at Cardiff University, thanks to substantial new funding from the Medical Research Council.

4 Jan 2012

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange announced today the successful results of the Phase 1/2 study of its drug candidate CF102 in the treatment of hepatocellular carcinoma.

4 Jan 2012

Ampio completes enrollment phase of Australian Ampion In Knee trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that it is has completed the expanded patient enrollment phase of its Ampion In Knee (AIK) trials in Australia.

3 Jan 2012

Scientists show how HCV virus hijacks miR-122 in liver cells

Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.

2 Jan 2012

Van Andel studies distinguish cancer subtypes and provide promising new drug targets

Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments.

30 Dec 2011

IL-1 gene inactivation may reduce severe clinical complications of atherosclerosis

Atherosclerosis is a disease of the major arterial blood vessels. It is one of the major causes of heart attack and stroke. The proinflammatory molecule IL-1 has been linked to atherosclerosis and a clinical trial has been launched in which an antibody specific for IL-1-beta is being studied for its effects on the severe clinical complications of atherosclerosis.

28 Dec 2011

New approach may prevent septic shock

Researchers of VIB and UGent have discovered a new approach to preventing septic shock, an often fatal extreme inflammatory reaction of the body. It is the most frequent cause of death at intensive care departments in hospitals.

28 Dec 2011

Synthetic drugs treat Crohn's disease in mice

A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.

26 Dec 2011

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.

26 Dec 2011

LANL's top 10 science stories of 2011

Los Alamos National Laboratory's top 10 science stories of 2011 illustrate the broad variety of scientific excellence that's the hallmark of the Laboratory. This year's stories include alternative energy research, world record magnetic fields, disease tracking, the study of Mars, climate change, fuel cells, solar wind, and magnetic reconnection.

26 Dec 2011

Researchers discover key interaction at heart of promising new treatment for Fabry disease

A research team led by biochemist Scott Garman at the University of Massachusetts Amherst has discovered a key interaction at the heart of a promising new treatment for a rare childhood metabolic disorder known as Fabry disease.

23 Dec 2011

Reverse spectroscopy eliminates background noise and cleans up images

Optical techniques enable us to examine single molecules, but do we really understand what we are seeing? After all, the fuzziness caused by effects such as light interference makes these images very difficult to interpret.

23 Dec 2011

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers - leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego.

23 Dec 2011

Researchers identify molecules that can stimulate heart muscle regeneration

Damaged heart tissue is not known for having much inherent capacity for repair. But now, scientists are closing in on signals that may be able to coax the heart into producing replacement cardiac muscle cells. Using a zebrafish model system, researchers have identified a family of molecules that can stimulate stem cells to develop into beating heart muscle cells.

23 Dec 2011

New silk-based microneedle system for controlled-release drug delivery

Bioengineers at Tufts University School of Engineering have developed a new silk-based microneedle system able to deliver precise amounts of drugs over time and without need for refrigeration. The tiny needles can be fabricated under normal temperature and pressure and from water, so they can be loaded with sensitive biochemical compounds and maintain their activity prior to use. They are also biodegradable and biocompatible.

22 Dec 2011

Researchers discover how c-MYC facilitates tumor growth

Cancer cells are essentially immortal. The acquisition of an unlimited capacity to divide - the process of immortalization - is a central event in the genesis of tumors. Normally, cells are subject to stringent mechanisms which control their proliferation. Together these ensure that pre-malignant cells are induced to enter a senescent, non-dividing state or to undergo apoptosis, i.e. commit suicide.

22 Dec 2011

Molecule News and Research

Bionomics, Ironwood partner to develop and commercialize novel anti-anxiety compound

First study to elucidate how statins reduce activation of abnormal blood clotting

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

Study reveals possibility to selectively target and block crucial microRNA in liver cancer

MRC-funded study to explore pancreatic cancer

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Ampio completes enrollment phase of Australian Ampion In Knee trials

Scientists show how HCV virus hijacks miR-122 in liver cells

Van Andel studies distinguish cancer subtypes and provide promising new drug targets

IL-1 gene inactivation may reduce severe clinical complications of atherosclerosis

New approach may prevent septic shock

Synthetic drugs treat Crohn's disease in mice

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

LANL's top 10 science stories of 2011

Researchers discover key interaction at heart of promising new treatment for Fabry disease

Reverse spectroscopy eliminates background noise and cleans up images

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers identify molecules that can stimulate heart muscle regeneration

New silk-based microneedle system for controlled-release drug delivery

Researchers discover how c-MYC facilitates tumor growth

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News